Number of eligible patients: CDEC discussed the uncertainty in the number of patients with moderately serious to serious hemophilia B in Canada eligible for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some people who will be labeled as obtaining gentle